Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples

Markus Riester, Wei Wei, Levi Waldron, Aedin C. Culhane, Lorenzo Trippa, Esther Oliva, Sung Hoon Kim, Franziska Michor, Curtis Huttenhower, Giovanni Parmigiani, Michael J. Birrer

Research output: Contribution to journalArticlepeer-review

Abstract

Background Ovarian cancer causes more than 15000 deaths per year in the United States. The survival of patients is quite heterogeneous, and accurate prognostic tools would help with the clinical management of these patients. Methods We developed and validated two gene expression signatures, the first for predicting survival in advanced-stage, serous ovarian cancer and the second for predicting debulking status. We integrated 13 publicly available datasets totaling 1525 subjects. We trained prediction models using a meta-analysis variation on the compound covariable method, tested models by a leave-one-dataset-out procedure, and validated models in additional independent datasets. Selected genes from the debulking signature were validated by immunohistochemistry and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) in two further independent cohorts of 179 and 78 patients, respectively. All statistical tests were two-sided. Results The survival signature stratified patients into high-and low-risk groups (hazard ratio = 2.19; 95% confidence interval [CI] = 1.84 to 2.61) statistically significantly better than the TCGA signature (P =. 04). POSTN, CXCL14, FAP, NUAK1, PTCH1, and TGFBR2 were validated by qRT-PCR (P

Original languageEnglish (US)
Article numberdju048
JournalJournal of the National Cancer Institute
Volume106
Issue number5
DOIs
StatePublished - May 14 2014
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples'. Together they form a unique fingerprint.

Cite this